Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®... | April 21, 2023

Related Keywords

Beerse ,Region Flamande ,Belgium ,Italy ,Germany ,France ,Spain ,United Kingdom ,London ,City Of ,Japan ,Janssen Cilag Gmb ,Martin Vogel ,Magda Palhota ,Peter Lebowitz ,Gerhardt Attard ,Janssen Cilag Gm ,Urology Care Foundation ,Exchange Commission ,Drug Administration ,Companies Of Johnson ,Janssen Research Development ,European Medicines Agency ,University College London ,None Of The Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies ,Johnson ,Tesaro Inc ,European Commission ,Janssen Pharmaceutical Companies Of Johnson ,Drug Administration Seeking Approval Of Niraparib ,European Union ,Janssen Cilag International ,Janssen Biotech Inc ,Professor Gerhardt Attard ,Area Lead Oncology ,Hazard Ratio ,Confidence Interval ,Global Therapeutic Area Head ,Janssen Research ,New Drug Application ,Janssen Biotech ,European Economic Area ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Advanced Prostate Cancera Review ,Current Therapies ,Cold Spring Harb Perspect ,Genomic Profiling ,Literature Review ,Advanced Prostate Cancer ,Associated Homologous Recombination Repair Gene ,Prospective Cohort Study ,Prostate Cancer ,Indolent Prostate Cancer ,Early Age ,Combination With Abiraterone Acetate ,Prednisone Versus Abiraterone Acetate ,Participants With Metastatic Prostate Cancer ,With Abiraterone Acetate ,Homologous Recombination Repair Gene Alterations ,Second Interim Analysis ,Abiraterone Acetate ,Metastatic Castration Resistant Prostate ,Janssen Submits New Drug Application ,Drug Administration Seeking Approval ,Abiraterone Acetate Dual Action Tablet ,Plus Prednisone ,First Line Targeted Treatment ,Metastatic Castration Resistant Prostate Cancer ,Participants With Deleterious Germline ,Somatic Homologous Recombination Repair ,Enters Worldwide Collaboration ,License Agreement ,What You Should ,World Treatment Patterns ,Johnson Stock Exchange ,News ,Information ,Press Release ,1 ,Pril ,023 ,The ,Janssen ,Harmaceutical ,Companies ,F ,Nnounced ,Oday ,Hat ,European ,Commission ,Gas ,Granted ,Marketing ,Authorisation ,Or Jnj Us4781601046 ,